<DOC>
	<DOCNO>NCT02006277</DOCNO>
	<brief_summary>This study intend evaluate sensory attribute estimate relative bioavailability three prototype oral formulation . Subjects either taste 75-mg dose `` swirl spit '' ( Cohort 1 ) receive five oral single 250-mg dos washout period least 14 day ( Cohort 2 ) .</brief_summary>
	<brief_title>A Study To Taste Three New Types Of Crizotinib Formulation In Comparison Of An Oral Solution And To Measure The Amount Of Crizotinib In The Body After These Formulations Are Orally Given , Relative To Capsule Formulation</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Crizotinib</mesh_term>
	<criteria>Healthy male and/or female subject nonchildbearing potential age 18 55 year , inclusive . Healthy define clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure pulse rate measurement , 12 lead ECG clinical laboratory test . Female subject non child bear potential must Body Mass Index ( BMI ) 17.5 30.5 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . Pregnant nursing female ; female childbearing potential . Use prescription nonprescription drug dietary supplement within 7 day 5 half life ( whichever longer ) prior first dose study medication . Limited use non prescription medication believe affect subject safety overall result study may permit casebycase basis follow approval sponsor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>healthy volunteer</keyword>
	<keyword>taste</keyword>
	<keyword>bioavailability</keyword>
</DOC>